Millipore hopes its $23m (€18m) swoop for Guava Technologies will draw attention away from the underperformance of its bioprocess division, revenue from which fell 6 per cent in Q4 to $214m (€165m) and 2 per cent for 2008 overall.
Industrial processing giant Pall is stepping up global promotion efforts for its Allegro platform as the market for single-use drug manufacturing options, estimated to be worth around $400m (€308m), continues to expand.
US contract developer Xcelience has added small-scale batch production capability to its repertoire of good manufacturing proactice (GMP) accredited production services in a bid to attract drug firms working with small quantities of API.
Canadian contract manufacturing organisation PharmEng International, which has been hit by dwindling cash reserves in recent months, got a boost last week when its subsidiary Keata Pharma was awarded a C$3m research grant.
Thermo Fisher Scientific hopes that the web functionality offered by the latest generation of its Darwin LIMS system will help it become the natural selection for drug makers seeking an all-in-one QA solution.
D3 Technology hopes its new SERS-based cleaning verification test, that follows FDA guidelines, will prove attractive to drugmakers looking to expedite the cleaning process and cut downtime between production runs.